Related Experiment Video
Updated: May 7, 2026
09:51
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
11.9K
In vitro evaluation of TLR4 agonist activity: formulation effects
Ayesha Misquith1, H W Millie Fung1, Quinton M Dowling1
1Infectious Disease Research Institute (IDRI), 1124 Columbia Street, Ste 400, Seattle, WA 98104, USA.
Colloids and Surfaces. B, Biointerfaces
|October 15, 2013
Summary
Evaluating vaccine adjuvants in vitro is crucial for high-throughput screening. However, the most potent in vitro activators, like GLA formulations, may not always correlate with the strongest in vivo adjuvant activity.
Area of Science:
- Vaccinology
- Immunology
- Formulation Science
Background:
- In vitro evaluation of vaccine adjuvants offers higher throughput than in vivo studies.
- Adjuvant formulations vary widely, impacting their bioactivity and correlation with in vivo efficacy.
- The influence of formulation on in vitro adjuvant assays and in vivo outcomes remains poorly understood.
Purpose of the Study:
- To assess the in vitro bioactivity of distinct formulations of the synthetic Toll-like receptor 4 (TLR4) agonist Glucopyranosyl Lipid A (GLA).
- To investigate the correlation between in vitro bioactivity and in vivo adjuvant efficacy for different GLA formulations.
- To highlight formulation considerations for interpreting in vitro adjuvant assay data.
Main Methods:
- Utilized the Limulus amebocyte lysate (LAL) assay for endotoxin detection.
- Employed a human macrophage cellular cytokine production assay to measure bioactivity.
- Compared in vitro results with published in vivo adjuvant activity data for four GLA formulations: GLA-AF, GLA-SE, GLA-LS, and GLA-Alum.
Main Results:
- Demonstrated significant differences in in vitro bioactivity among the four GLA formulations.
- Showcased the impact of GLA localization within the formulation on its in vitro potency.
- Observed that formulations highly potent in vitro did not necessarily exhibit the strongest in vivo adjuvant effects.
Conclusions:
- The in vitro potency of vaccine adjuvants does not always predict their in vivo efficacy.
- Formulation parameters critically influence the interpretation of in vitro adjuvant activity data.
- Careful consideration of formulation is essential for developing reliable in vitro assays for vaccine adjuvants.
